Pulmonary Fibrosis is a Subset of Interstitial Lung Disease
Interstitial lung disease (ILD) is the umbrella term for a large, heterogeneous group of over 200 lung disorders affecting the lung interstitium, while pulmonary fibrosis specifically refers to the scarring/fibrotic component that can develop in many—but not all—ILDs 1.
The Hierarchical Relationship
Interstitial Lung Disease (ILD): The Broad Category
ILD encompasses diverse conditions characterized by inflammation and/or fibrosis of the lung parenchyma, including 1:
- Idiopathic interstitial pneumonias (iNSIP, DIP, COP, AIP, LIP)
- Autoimmune-related ILDs (rheumatoid arthritis, systemic sclerosis, myositis, Sjögren's)
- Exposure-related ILDs (hypersensitivity pneumonitis, asbestosis, silicosis, medication-induced)
- ILDs with cysts/airspace filling (Langerhans cell histiocytosis, lymphoproliferative disorders, pulmonary alveolar proteinosis)
- Sarcoidosis
- Idiopathic pulmonary fibrosis (IPF)
Pulmonary Fibrosis: The Scarring Process
Pulmonary fibrosis represents the end result of chronic injury and repair in the lung interstitium, characterized by:
- Excessive collagen deposition
- Architectural distortion with traction bronchiectasis
- Honeycombing (in advanced cases)
- Irreversible loss of functional lung tissue
Not all ILDs develop fibrosis—some remain purely inflammatory (like acute eosinophilic pneumonia) or may resolve completely with treatment 1, 2.
Clinical Distinction: Progressive Pulmonary Fibrosis (PPF)
The 2022 ATS/ERS/JRS/ALAT guidelines introduced the critical concept of Progressive Pulmonary Fibrosis (PPF)—a behavior pattern rather than a specific diagnosis 1. PPF occurs when non-IPF ILDs develop progressive fibrosis despite treatment, defined by ≥2 of the following within one year:
- Worsening respiratory symptoms
- Physiological decline: FVC decline >5% predicted OR DLCO decline >10% predicted
- Radiological progression: increased traction bronchiectasis, new reticulation, new/increased honeycombing, or increased lobar volume loss
Approximately 18-32% of non-IPF ILDs will develop PPF, exhibiting an IPF-like progressive course 1, 3. This distinction matters because PPF patients may benefit from antifibrotic therapy (nintedanib, pirfenidone) regardless of their underlying ILD diagnosis 1, 4.
Key Practical Differences
Prognosis and Behavior
- IPF (a specific fibrotic ILD): Median survival 2-5 years, virtually all patients progress 4, 5
- Non-fibrotic ILDs: Variable course; many stabilize or improve with immunosuppression 6, 7
- Fibrotic non-IPF ILDs: Heterogeneous—some remain stable, others develop PPF 1, 3
SARD-ILD (systemic autoimmune rheumatic disease-ILD) demonstrates significantly better 5-year survival (mean 56 months) compared to IPF (mean 33.6 months), with some subtypes like antisynthetase syndrome showing functional improvement rather than decline 5.
Treatment Implications
- Non-fibrotic ILDs: Primarily immunosuppression (corticosteroids, mycophenolate, rituximab, tocilizumab) 4, 6
- IPF: Antifibrotics (nintedanib/pirfenidone) are first-line; immunosuppression is contraindicated 1, 4
- PPF (non-IPF with progressive fibrosis): Antifibrotics now recommended, reducing FVC decline by 44-57% 1, 4
Diagnostic Approach
The diagnosis hinges on etiology identification through comprehensive exposure history (occupational, environmental, medication, autoimmune screening) rather than focusing solely on histologic patterns 7. HRCT patterns help distinguish:
- UIP pattern (peripheral, basal, honeycombing): Typical for IPF but seen in <20% of SARD-ILD 5
- NSIP pattern (ground-glass with reticulation): Common in CTD-ILD, may progress to fibrosis 1
- Combined patterns: Frequent in non-IPF ILDs, making classification challenging 2
Common Pitfalls to Avoid
- Assuming all fibrosis is IPF: Many ILDs develop secondary fibrosis but have different prognoses and treatments 1, 7
- Missing the underlying cause: A thorough exposure/medication/autoimmune history is essential—the etiology determines treatment, not just the fibrotic pattern 7
- Overlooking PPF development: Regular monitoring (every 3-6 months) with PFTs and imaging is critical to identify progression requiring treatment escalation 1
- Ignoring complications: Both fibrotic and non-fibrotic ILDs can develop pulmonary hypertension (47-90% in CPFE), lung cancer (22-46%), and acute exacerbations (20-28%) 8, 9
Risk factors for PPF development in CTD-ILD include elevated KL-6, hSP-D, MMP-7, and CA-125; lower baseline FVC% predicted is protective 3.